H. Lee Moffitt Cancer Center & Research Institute

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy (2019) Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, Menevse AN, et al. Journal article Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation (2019) Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, et al. Journal article Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia (2019) Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, et al. Journal article Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors (2019) Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, et al. Journal article Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk (2019) Yang Y, Wu L, Shu X, Lu Y, Shu XO, Cai Q, Beeghly-Fadiel A, et al. Journal article Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus (2019) Buckley MA, Woods NT, Tyrer JP, Mendoza-Fandino G, Lawrenson K, Hazelett DJ, Najafabadi HS, et al. Journal article Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Fazio N, Carnaghi C, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019) Chan DL, Yao JC, Camaghi C, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al. Conference contribution SMARCB1 (INI-1)-Deficient Adenocarcinoma of the Sinonasal Tract: A Potentially Under-Recognized form of Sinonasal Adenocarcinoma with Occasional Yolk Sac Tumor-Like Features (2019) Shah AA, Jain D, Ababneh E, Agaimy A, Hoschar AP, Griffith CC, Magliocca KR, et al. Journal article Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution